YURAK ISHEMIK KASALLIGI MAVJUD BEMORLARDA INTERLEYKIN-6 AHAMIYATI
Vol. 2 No. 5 (2024), Articles
Vol. 2 No. 5 (2024)

YURAK ISHEMIK KASALLIGI MAVJUD BEMORLARDA INTERLEYKIN-6 AHAMIYATI

Articles
Published 2024-05-15
G`opirjonova D.D
Toshkent tibbiyot akademiyasi
Alyavi A.L
Toshkent tibbiyot akademiyasi
PDF
DOI

Keywords

Yurak ishemik kasalligi, biomarkerlar, yallig`lanish, interleykin-6

How to Cite

G`opirjonova D.D, & Alyavi A.L. (2024). YURAK ISHEMIK KASALLIGI MAVJUD BEMORLARDA INTERLEYKIN-6 AHAMIYATI. "Conference on Universal Science Research 2023", 2(5), 92–95. Retrieved from https://universalpublishings.com/index.php/cusr/article/view/5719
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Yallig`lanish bu yurak ishemik kasalligida (YuIK) ishtirok etuvchi muhim jarayon hisoblanadi. Metabolik stress, gemodinamik ortiqcha yuk va endoteliy va miyokard hujayralarida neyrogumaral giperaktivatsiyaga javoban interleykin (IL) 1 va 6 kabi yallig`lanishga qarshi sitokinlar chiqariladi. Dastlab, bu jarayon organizimni stresga moslashishini taminlaydi, ammo keyinchlik kasallik davrida ular endothelial va yurak disfunktsiyasi orqali miyokard fibroziga olib keladigan zararli ta`sirlarni keltirib chiqaradi. Tadqiqotlar shuni ko`rsatadiki yurak ishemik kasalligida bemorlarda interleykin(IL)6 yallig`lanish mediatori ko`payib ketadi.

PDF
DOI

References

Murphy, S.P.; Kakkar, R.; McCarthy, C.P.; Januzzi, J.L. Inflammation in Heart Failure. J. Am. Coll. Cardiol. 2020, 75, 1324–1340. [CrossRef] [PubMed]

Shirazi, L.F.; Bissett, J.; Romeo, F.M.J. Role of inflammation in heart failure. Curr. Atheroscler. Rep. 2017, 19, 27. [CrossRef] [PubMed]

Maggio, M.; Guralnik, J.M.; Longo, D.L.F.L. Interleukin-6 in aging and chronic disease: A magnificent pathway. J. Gerontol. A Biol.

Sci. Med. Sci. 2006, 61, 575–584. [CrossRef]

Chung, E.S.; Packer, M.; Lo, K.H.; Fasanmade, A.A.; Willerson, J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: Results of the anti-TNF therapy against congestive heart failure (ATTACH. Circulation 2003, 107, 3133–3140. [CrossRef] [PubMed]

Mann, D.L.; McMurray, J.J.; Packer, M.; Swedberg, K.; Borer, J.S.; Colucci, W.S.; Djian, J.; Drexler, H.; Feldman, A.; Kober, L.; et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109, 1594–1602. [CrossRef]

Markousis-Mavrogenis, G.; Tromp, J.; Ouwerkerk, W.; Devalaraja, M.; Anker, S.D.; Cleland, J.G.; Dickstein, K.; Filippatos, G.S.; van der Hast, P.; Lang, C.C. The clinical significance of interleukin-6 in heart failure: Results from the BIOSTAT-CHF study. Eur. J. Heart Fail. 2019, 6, 1–9. [CrossRef].

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.